Stocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Stocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems

Dow Jones05-07

By Ben Glickman

Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government contract revenue has trailed far behind commercial growth, but Palantir topped Wall Street estimates with the help of strong AI demand. Shares fell 6.8% to $23.46 post market.

Hims & Hers Health posted its second consecutive quarterly profit and raised its 2024 outlook. The company reported a sharp increase in revenue and subscribers in the first quarter. Shares rose 12% to $13.05 after hours.

Beyond's loss widened in the first quarter as revenue rose 0.3% and missed Wall Street expectations. The company said it was happy with its active customer and transaction growth in the first quarter, but was looking to focus more on acquiring customers who are likely to repeatedly shop on the site. Shares dropped 8.9% to $19.95 after hours.

T2 Biosystems said it had reached a distribution deal in Qatar and had converted an additional $15 million of a term loan into equity to reduce its debt. The company's loss narrowed in the first quarter after revenue rose 25% from a year earlier. Shares rose 17% to $4.25 in the late session.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

May 06, 2024 19:57 ET (23:57 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2433835252?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-07 07:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2433835252","market":"sg","top_or_hot":-1,"title":"Stocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government contract revenue has trailed far behind commercial growth, but Palantir topped Wall Street estimates with the help of strong AI demand. Shares fell 6.8% to $23.46 post market. \n</p>\n<p>\n  Hims &amp; Hers Health posted its second consecutive quarterly profit and raised its 2024 outlook. The company reported a sharp increase in revenue and subscribers in the first quarter. Shares rose 12% to $13.05 after hours. \n</p>\n<p>\n  Beyond's loss widened in the first quarter as revenue rose 0.3% and missed Wall Street expectations. The company said it was happy with its active customer and transaction growth in the first quarter, but was looking to focus more on acquiring customers who are likely to repeatedly shop on the site. Shares dropped 8.9% to $19.95 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/TTOO\">T2 Biosystems</a> said it had reached a distribution deal in Qatar and had converted an additional $15 million of a term loan into equity to reduce its debt. The company's loss narrowed in the first quarter after revenue rose 25% from a year earlier. Shares rose 17% to $4.25 in the late session. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2024 19:57 ET (23:57 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Palantir, Hims & Hers Health, Beyond, T2 Biosystems\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-07 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4543","symbol_name":"AI","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2433835252","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433835252","pubTimestamp":1715039820,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government contract revenue has trailed far behind commercial growth, but Palantir topped Wall Street estimates with the help of strong AI demand. Shares fell 6.8% to $23.46 post market.Hims & Hers Health posted its second consecutive quarterly profit and raised its 2024 outlook. The company reported a sharp increase in revenue and subscribers in the first quarter. Shares rose 12% to $13.05 after hours.Beyond's loss widened in the first quarter as revenue rose 0.3% and missed Wall Street expectations. The company said it was happy with its active customer and transaction growth in the first quarter, but was looking to focus more on acquiring customers who are likely to repeatedly shop on the site. Shares dropped 8.9% to $19.95 after hours.T2 Biosystems said it had reached a distribution deal in Qatar and had converted an addition","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4543":"AI","BK4585":"ETF&股票定投概念","BK4547":"WSB热门概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BYON":"BEYOND","PLTR":"Palantir Technologies Inc.","BK4139":"生物科技","BK4583":"猴痘概念","TTOO":"T2 Biosystems","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4023":"应用软件","BK4178":"家庭装饰零售"},"translate_title":"值得关注的股票：Palantir、Hims&Hers Health、Beyond、T2 Biosystems","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BYON":1,"PLTR":1,"TTOO":1},"content_text":"By Ben Glickman \n\n\n \n\n\n  Palantir's U.S. commercial revenue growth decelerated sequentially in the first quarter, increasing 40% compared to a 70% increase in the fourth quarter. U.S. government contract revenue has trailed far behind commercial growth, but Palantir topped Wall Street estimates with the help of strong AI demand. Shares fell 6.8% to $23.46 post market. \n\n\n  Hims & Hers Health posted its second consecutive quarterly profit and raised its 2024 outlook. The company reported a sharp increase in revenue and subscribers in the first quarter. Shares rose 12% to $13.05 after hours. \n\n\n  Beyond's loss widened in the first quarter as revenue rose 0.3% and missed Wall Street expectations. The company said it was happy with its active customer and transaction growth in the first quarter, but was looking to focus more on acquiring customers who are likely to repeatedly shop on the site. Shares dropped 8.9% to $19.95 after hours. \n\n\nT2 Biosystems said it had reached a distribution deal in Qatar and had converted an additional $15 million of a term loan into equity to reduce its debt. The company's loss narrowed in the first quarter after revenue rose 25% from a year earlier. Shares rose 17% to $4.25 in the late session. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2024 19:57 ET (23:57 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}